Real-World Multicenter Experience with Mepolizumab and Benralizumab in the Treatment of Uncontrolled Severe Eosinophilic Asthma Over 12 Months.
Moritz Z KayserNora DrickKatrin MilgerJan FugeNikolaus KneidingerStephanie KornRoland BuhlJürgen BehrTobias WelteHendrik SuhlingPublished in: Journal of asthma and allergy (2021)
Both mepolizumab and benralizumab are highly effective in the long-term treatment of SEA, with no clinically relevant differences in outcomes after 12 months of therapy. In both groups, improvements were similar after 6 and 12 months of therapy, underlining the feasibility of early treatment evaluation.